147 related articles for article (PubMed ID: 11600232)
1. Novel phthalazinone and benzoxazinone containing thiazolidinediones as antidiabetic and hypolipidemic agents.
Madhavan GR; Chakrabarti R; Kumar SK; Misra P; Mamidi RN; Balraju V; Kasiram K; Babu RK; Suresh J; Lohray BB; Lohrayb VB; Iqbal J; Rajagopalan R
Eur J Med Chem; 2001; 36(7-8):627-37. PubMed ID: 11600232
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives.
Madhavan GR; Chakrabarti R; Vikramadithyan RK; Mamidi RN; Balraju V; Rajesh BM; Misra P; Kumar SK; Lohray BB; Lohray VB; Rajagopalan R
Bioorg Med Chem; 2002 Aug; 10(8):2671-80. PubMed ID: 12057656
[TBL] [Abstract][Full Text] [Related]
3. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Sauerberg P; Pettersson I; Jeppesen L; Bury PS; Mogensen JP; Wassermann K; Brand CL; Sturis J; Wöldike HF; Fleckner J; Andersen AS; Mortensen SB; Svensson LA; Rasmussen HB; Lehmann SV; Polivka Z; Sindelar K; Panajotova V; Ynddal L; Wulff EM
J Med Chem; 2002 Feb; 45(4):789-804. PubMed ID: 11831892
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
[TBL] [Abstract][Full Text] [Related]
5. Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
Reddy KA; Lohray BB; Bhushan V; Reddy AS; Rao Mamidi NV; Reddy PP; Saibaba V; Reddy NJ; Suryaprakash A; Misra P; Vikramadithyan RK; Rajagopalan R
J Med Chem; 1999 Aug; 42(17):3265-78. PubMed ID: 10464013
[TBL] [Abstract][Full Text] [Related]
6. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Shimaya A; Kurosaki E; Nakano R; Hirayama R; Shibasaki M; Shikama H
Metabolism; 2000 Mar; 49(3):411-7. PubMed ID: 10726922
[TBL] [Abstract][Full Text] [Related]
7. Novel thieno oxazine analogues as antihyperglycemic and lipid modulating agents.
Das SK; Reddy KA; Abbineni C; Iqbal J; Suresh J; Premkumar M; Chakrabarti R
Bioorg Med Chem Lett; 2003 Feb; 13(3):399-403. PubMed ID: 12565938
[TBL] [Abstract][Full Text] [Related]
8. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
9. Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Sohda T; Mizuno K; Momose Y; Ikeda H; Fujita T; Meguro K
J Med Chem; 1992 Jul; 35(14):2617-26. PubMed ID: 1635060
[TBL] [Abstract][Full Text] [Related]
10. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
11. [The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Jazet IM; Meinders AE
Ned Tijdschr Geneeskd; 2001 Aug; 145(32):1541-7. PubMed ID: 11525086
[TBL] [Abstract][Full Text] [Related]
12. Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Suzuki A; Yasuno T; Kojo H; Hirosumi J; Mutoh S; Notsu Y
Jpn J Pharmacol; 2000 Oct; 84(2):113-23. PubMed ID: 11128033
[TBL] [Abstract][Full Text] [Related]
13. Novel euglycemic and hypolipidemic agents: Part-2. Antioxidant moiety as structural motif.
Reddy KA; Lohray BB; Bhushan V; Reddy AS; Kishore PH; Rao VV; Saibaba V; Bajji AC; Rajesh BM; Reddy KV; Chakrabarti R; Rajagopalan R
Bioorg Med Chem Lett; 1998 May; 8(9):999-1002. PubMed ID: 9871696
[TBL] [Abstract][Full Text] [Related]
14. Studies on the euglycemic and hypolipidemic potentials of the novel indole analogue of thiazolidinedione, DRF 2189.
Chakrabarti R; Vikramadithyan RK; Dileepkumar T; Kumar KB; Kumar MP; Misra P; Rao PB; Lohray VB; Lohray BB; Rajagopalan R
Arzneimittelforschung; 1999 Nov; 49(11):905-11. PubMed ID: 10604043
[TBL] [Abstract][Full Text] [Related]
15. 5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.
Koyama H; Boueres JK; Han W; Metzger EJ; Bergman JP; Gratale DF; Miller DJ; Tolman RL; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
Bioorg Med Chem Lett; 2003 May; 13(10):1801-4. PubMed ID: 12729668
[TBL] [Abstract][Full Text] [Related]
16. Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones.
Reddy KA; Lohray BB; Bhushan V; Bajji AC; Reddy KV; Reddy PR; Krishna TH; Rao IN; Jajoo HK; Rao NV; Chakrabarti R; Dileepkumar T; Rajagopalan R
J Med Chem; 1999 Jun; 42(11):1927-40. PubMed ID: 10354401
[TBL] [Abstract][Full Text] [Related]
17. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity.
Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R
Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504
[TBL] [Abstract][Full Text] [Related]
18. [Thiazolidinediones--a new class of oral antidiabetic drugs].
Jermendy G; Csermely P
Orv Hetil; 2001 Jul; 142(29):1547-54. PubMed ID: 11494746
[TBL] [Abstract][Full Text] [Related]
19. [Studies on compounds with antioxidant activity--development of hypoglycemic agents, troglitazone (CS-045)].
Yoshioka T; Fujita T
Yakugaku Zasshi; 1997 Sep; 117(9):597-610. PubMed ID: 9357328
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, hypoglycaemic, hypolipidemic and PPARγ agonist activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones.
Khazi MI; Belavagi NS; Kim KR; Gong YD; Khazi IA
Chem Biol Drug Des; 2013 Aug; 82(2):147-55. PubMed ID: 23581650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
